amber_raza

4 ms·

1.
by amber_raza 9mo ago
You found the ultimate edge case. The 'Prestige Proxy' (NEJM = Truth) essentially masks that individual's actual track record. While we might be able to detect 'Insular Citation Clusters' mathematically to flag syst
2.
by amber_raza 9mo ago
You just articulated the 'Holy Grail' of automated appraisal. Detecting bias across a career is a massive graph problem compared to checking a single paper. It essentially requires auditing an entire bibliography before synthesis.
3.
by amber_raza 9mo ago
That is a fair distinction. My default right now is Clinical Safety. I prioritize high-grade evidence to prevent harm at the bedside. However, for Research/Discovery, you are absolutely right. Excessive 'Gatekeeping' can slow
4.
by amber_raza 9mo ago
Thanks! I just took a look at MediSearch. It looks really clean. You are definitely right that Live APIs come with their own headaches (mostly latency and rate limits). For now, I chose this path to avoid the infrastructure overhead of main
5.
by amber_raza 9mo ago
100%. The 'Alt-Tab' tax is the biggest barrier to adoption. Starting as a 'second screen' is just step one; deep integration into the workflow is the eventual north star.
6.
by amber_raza 9mo ago
I hear that frustration. The reality is that the 15-minute visit model leaves zero time for 'deep dives', which leads to the friction you described. My hope is that by reducing the time it takes to verify a paper from 20 minutes t
7.
by amber_raza 9mo ago
You hit the nail on the head regarding the 'semantic gap'. Currently, I handle this via Smart Routing. The engine analyzes the intent of your query (e.g. identifying if you’re looking for an RCT, a specific guideline, or drug dosi
8.
by amber_raza 9mo ago
This is a fantastic critique. Spot on. Freshness without appraisal is just an accelerated firehose of noise. 1. The Garbage Filter: Right now, I rely on a strict Hierarchy of Evidence to mitigate this (prioritizing Cochrane/Meta-analys
9.
by amber_raza 9mo ago
That is a fair critique. The frontier models are getting incredible at general reasoning. The gap Evidex fills isn't 'Intelligence'. It is Provenance and Liability. Strict Sourcing: Even advanced models can hallucinate a plau
10.
by amber_raza 9mo ago
Fair point on the Privacy Policy link. That definitely slipped through the cracks in the launch rush. I just pushed a fix to add it to the footer now. Re: the trackers: The SVG is just the icon inside the Clerk login button, but you're
11.
by amber_raza 9mo ago
Haha, ouch. I promise it’s just me—I just spent 20 minutes rewriting that comment because I didn't want to sound like an idiot explaining search to a search engineer. I'll take it as a sign to dial back the formatting next time.
12.
by amber_raza 9mo ago
Thanks, Joel! This is exactly the kind of clinical workflow I built 'Case Mode' for. I will send you an email shortly to get connected. I'd love to get your teams set up with a pilot instance. Appreciate the reach out.
13.
by amber_raza 9mo ago
Whoa. $150M ARR on ads is a wild stat. Thanks for sharing that source. It really validates the thesis that unless the user pays (SaaS), the Pharma companies are the real customers.
14.
by amber_raza 9mo ago
Appreciate the transparency and the insight from a fellow builder. You are spot on that maintaining a fresh, high-quality index at scale is the 'hard problem' (and why tools like OpenEvidence are expensive). However, I found that
15.
by amber_raza 9mo ago
That sounds like a fascinating project. To answer your question: In the biomedical world, the 'Time-Series' equivalent is Patient Telemetry (Continuous Glucose Monitors, ICU Vitals, Wearables). The Question Researchers Ask: '
16.
by amber_raza 9mo ago
Great question. I haven't seen banner ads on OpenEvidence yet, but the 'hidden tax' of free tools is often Publisher Bias. Users have noted that some current tools heavily overweight citations from 'Partner Journals&#x27
17.
by amber_raza 9mo ago
Great questions. 1. Prioritization: I instruct the model to prioritize evidence in this hierarchy: Meta-Analyses & Systematic Reviews > RCTs > Observational Studies > Case Reports. It explicitly deprioritizes non-human studies
18.
by amber_raza 9mo ago
Thanks for the feedback—this is helpful. 1. Re: Clerk/uBlock: You were spot on. The default Clerk domain often gets flagged by strict blocklists. I just updated the DNS records to serve auth from a first-party subdomain (clerk.getevide
19.
by amber_raza 9mo ago
Oof, good catch! I must have left the test keys active in the deployment config. Swapping them to production keys right now. Thanks for the heads up!
20.
Show HN: Evidex – AI Clinical Search (RAG over PubMed/OpenAlex and SOAP Notes)(getevidex.com)
36 points by amber_raza 9mo ago|41 comments